Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
A Phase I/II Trial of Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
Sponsor: Puma Biotechnology, Inc.
A PHASE1/PHASE2 clinical study on Breast Cancer, this trial is completed. The trial is conducted by Puma Biotechnology, Inc. and has accumulated 8 data snapshots since 2010. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Oct 2018 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Oct 2018 [monthly]
Completed PHASE1_PHASE2
▶ Show 3 earlier versions
-
Dec 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
-
Feb 2017 — Dec 2017 [monthly]
Completed PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1_PHASE2
First recorded
Apr 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Puma Biotechnology, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .